Van Cleef Asset Management cut its position in Pfizer Inc. (NYSE:PFE) by 0.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 91,709 shares of the biopharmaceutical company’s stock after selling 374 shares during the period. Van Cleef Asset Management’s holdings in Pfizer were worth $2,960,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in PFE. Proficio Capital Partners bought a new position in shares of Pfizer during the fourth quarter worth approximately $2,059,000. Creative Planning raised its stake in shares of Pfizer by 15.7% in the fourth quarter. Creative Planning now owns 660,706 shares of the biopharmaceutical company’s stock worth $21,328,000 after buying an additional 89,688 shares during the last quarter. Atalanta Sosnoff Capital raised its stake in shares of Pfizer by 12.1% in the fourth quarter. Atalanta Sosnoff Capital now owns 1,935,494 shares of the biopharmaceutical company’s stock worth $62,478,000 after buying an additional 209,124 shares during the last quarter. Baystate Wealth Management raised its stake in shares of Pfizer by 1.8% in the fourth quarter. Baystate Wealth Management now owns 28,138 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 508 shares during the last quarter. Finally, Verde Servico Internacionais acquired a new stake in shares of Pfizer during the fourth quarter worth about $24,213,000.

Shares of Pfizer Inc. (NYSE:PFE) traded up 0.43% during mid-day trading on Friday, reaching $30.71. 31,444,403 shares of the company’s stock traded hands. The stock has a market capitalization of $189.57 billion and a PE ratio of 23.06. The company’s 50-day moving average price is $31.87 and its 200-day moving average price is $33.24. Pfizer Inc. has a 12-month low of $28.47 and a 12-month high of $36.46.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.09. The company had revenue of $12.10 billion for the quarter, compared to analyst estimates of $11.56 billion. During the same quarter last year, the company earned $0.57 EPS. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post $2.18 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 2nd. Investors of record on Friday, February 5th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, February 3rd. This represents a $1.20 annualized dividend and a dividend yield of 3.91%. This is a positive change from Pfizer’s previous quarterly dividend of $0.24.

A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, January 18th. Jefferies Group cut their price target on Pfizer from $48.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, January 14th. Barclays reiterated a “neutral” rating and issued a $34.00 price target on shares of Pfizer in a research note on Tuesday, January 5th. Atlantic Securities reiterated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research note on Tuesday, January 5th. Finally, Cowen and Company reiterated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Wednesday, December 2nd. Six research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.